Mar 13 2026 This Week in Cardiology

Beta-blocker in non-obstructive hypertrophic cardiomyopathy, a head-to-head apixaban vs rivaroxaban RCT, diltiazem vs metoprolol combined with DOAC, and the accuracy of smart watches for AF are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only . To read a partial transcript or to comment, visit: I Listener Feedback EMPATICC trial II Beta-blocker in Non-obstructive HCM BB vs Calcium Channel Blocker in Non-obstructive HCM RCT of Metoprolol in Patients With Obstructive HCM III Apixaban vs Rivaroxaban for Bleeding Risk COBRRA Trial AMPLIFY Trial (Apixaban) EINSTEIN Trial (Rivaroxaban) IV Diltiazem vs Metoprolol When Combined with DOAC Risk for Bleeding in AF Patients Using Apixaban or Rivaroxaban With Diltiazem V Actual Clinical Use of Smart Watches CIRCA-DOSE Original Trial Wearable Smartwatches for AF Detection After Ablation You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. Questions or feedback, please contact news@medscape.net

You can listen to Mar 13 2026 This Week in Cardiology online on Radio and Podcast. Open the player on this page to stream the available audio.

Mar 13 2026 This Week in Cardiology is an episode from This Week in Cardiology by Medscape Podcasts.

This episode is 31:54 long.

This episode was published on Mar 13, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from This Week in Cardiology when more episodes are available from the podcast feed.